How The Firm Strategy Affect The Emergence Of The Genomic Industry?

Over the last 10 years scientists have been involved in the progression and completion of the Human Genome Project. "Scientists working on this project have developed detailed maps that identify the

Before discussion of the ethical, legal and social issues can be successful, some background information is needed. For example, why is the goal of mapping the human genome important? Who is going to benefit or at least be affected by this new

1. Identify potential sources of synergy in the proposed acquisition of Star Genomics. Identify a set of problems that the acquisition may create. How can Pills & Co. address them? From the strategic viewpoint, does it appear to be a sensible acquisition for Pills & Co.?

Today we live in a very technologically advanced society. Scientists are continually discovering new things about the world and the way things work. "In the 1980ís, it was becoming increasingly apparent to many scientists that an understanding of basic biology would be greatly enhanced if the detailed structure of DNA was understood" (Mehlman, 1998). Thus began what has become know as The Human Genome Project which is "the mapping of all our

The book “from Alchemy to IPO the business of Biotechnology” is a synopsis of the biotech industry from its inception to late 1900’s . Author Cynthia Robbins – Roth writes a first hand narration from amidst the blooming industry as she was one of the first senior scientist to be recruited by Genentech. The book gives a complete picture from the roots of biotech , the major milestones achieved and the process of getting the product out to the market. It also covers the financers, venture capitalist and the common man’s view of the biotech industry from time to time, during its progression.

The DNA sequence of the entire human genome was pieced together after a greatly anticipated 13 years, which allowed scientists and biological researchers to establish the genetic make-up of proteins, which essentially make up the human body. The Human Genome Project (HGP) ‘sequenced only "euchromatic" regions of the genome, which make up about 90% of the genome’ (En.wikipedia.org, 2016), which consists of, more or less, a majority of the DNA sequences in humans. Unlocking this huge amount of biological knowledge was exciting, but definitely slightly daunting, as these DNA sequences had to be identified in

In June 2000, the publicly funded Human Genome Project (HGP) and the private firm Celera Genomics Inc. announced that they had completed sequencing the human genome. This unprecedented accomplishment is expected to enable doctors to diagnose, treat and even prevent numerous genetic diseases. As these two entities worked on sequencing the human genome, there was also a separate and less publicized race to patent as many human genes as possible.

The Human Genome Project also referred to as HGP, has really captivated the world at the birth of the 21st Century and it has surely revolutionized the biology field. The project itself commenced officially in 1990 and scheduled for 15 years duration. HGP is so vast and complicated in nature that the most essential goals of the project had to be narrowed down to six; Identify approximately 30,000 genes in human DNA, determine 3 billion sequences of chemical base pairs which compose human DNA, Storage of developed information in databases, improve data analysis tools, transfer related technologies to the private sector and address the (ELSI) – Ethical, Legal, and Social Issues related to HGP. The total US HGP came with a huge price tag of around 3 billion US dollars.

DNA DTC is a company whose genetic products and services includes research, exome sequencing, and whole genome sequencing, but tests carry a steep price tag. Another company, Genelex is different from the previous companies, and specializes in paternity and pharmacogenomics, which simplified, is the study of individualized effect of drugs based on genetics. Genelex and other companies similar to them could be a threat by repositioning themselves, to combat health based genomic sequencing.

Myriad Genetics Inc., the court held the position that although Myriad located and sequenced the BRCA1 and BRCA2 genes, extensive effort alone would not transform the discovery into a patent eligible composition of matter . This position taken by the court reiterated Myriad’s claimed invention was routine and lacked inventiveness. Therefore, although the “obvious to try” test may seem to tip the scale in favour of Human gene patents, case law shows this is not the view the Judiciary holds, thus Human genes ultimately do not meet the non-obviousness

Research on our genetic composition is one of the more intricate researches because of its risk, cost and required effort. But understanding the blueprint of the human race is equally important that is why researchers are still determined to learn more about it. Genes are also very difficult to understand, because they are so complex and basically define what we are. A better understanding of genes and our DNA can lead to revolutionary medical advancements. (Healthcare Infographics, 2014)

Other players in the biotechnology industry such as Celmatix (a fertility genetic testing company) wants to partner with 23andme so that Celmatix can access the millions of user’s DNA that 23andme has collected, while they have done extensive research and testing to find solutions and treatments for infertility. It seems that even big players in this industry are looking to access 23andme’s data collection through partnerships and business deals, but cannot actually substitute 23andme because they do not have access to the millions of genetic information that 23andme has

Despite many of the overwhelming benefits future genomic research can provide, there are numerous foreseeable drawbacks, or at least considerations that need to be taken into account. These discoveries will hold the power to change us and our world in ways we cannot fully grasp in terms of long term impacts. Similar situations in history are important points for reflection as they remind us that what seems great in the moment can have

The ultimate goal of the HGP is to provide an encyclopedia of detailed information of the location, structure and function of the complete set of human genes. The HGP also loyally supports and sponsors genome studies on other organisms

From 1992 onwards, the NCBI has held the responsibility to increase the availability of the GenBank DNA sequence database. This happened to be a turning point in bioinformatics as this initiative encouraged the collaboration of scientists from different countries to contribute to the project.